Friedreich Ataxia
Conditions
Brief summary
This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.
Interventions
DRUGDT-216P2
DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.
DRUGSaline
Normal saline solution will be used as placebo control.
Sponsors
Design Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Participants must be 18-45 years of age inclusive, at the time of signing the informed consent. * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG. * Agree to abstain from strenuous physical activity outside of daily norm, until end of study. * Body mass index between 16 and 32 kg/m2 (inclusive) at screening; weight should be \<= 100 kg at screening. * Male and/or female using protocol defined and regulatory approved contraception. * Capable of giving signed informed consent.
Exclusion criteria
* Any concomitant medical condition that in the opinion of the investigator, puts the participant at risk or precludes participant from completing the study protocol. * Any clinically significant nonmedical conditions and psychiatric disorders that could put the participant at higher risk for participation in the study, influence the participant's ability to participate in the study, or interfere with interpretation of the participant's study results, in the opinion of the investigator. * Is not willing to comply with the contraceptive requirements during the study period, as per protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of treatment emergent adverse events (TEAEs) | From first dose to end of study, Day 30 post first dose administration. | To evaluate the safety and tolerability of single ascending doses of DT-216P2 in normal healthy participants by frequency of treatment-emergent adverse events (TEAEs). |
Secondary
| Measure | Time frame |
|---|---|
| Maximum Plasma Concentration (Cmax) of DT-216P2 | Pre-dose and up to 240 hours post first dose for both SC and IV infusion. |
| Time to Maximum Plasma Concentration (Tmax) of DT-216P2 | Pre-dose and up to 240 hours post first dose for both SC and IV infusion. |
| Area Under the Concentration-time Curve (AUC) of DT-216P2 | Pre-dose and up to 240 hours post first dose for both SC and IV infusion. |
Countries
Australia
Contacts
Primary ContactUyen Nguyen, BS
Backup ContactMatthias Kurth, MD, PhD
Outcome results
None listed